Freestone Grove Partners’s Supernus Pharmaceuticals SUPN Stock Holding History
Bought
Maintained
Sold
Other funds holding SUPN
Freestone Grove Partners's SUPN Position: Q3 2026 in Review
Freestone Grove Partners sold out of Supernus Pharmaceuticals (SUPN) in Q3 2026, closing a stake of 316,398 shares — an estimated $14.7M sold.
Freestone Grove Partners first reported a position in SUPN in Q4 2025 and held it in 3 quarters. The position peaked at $33.1M in Q1 2026. 294 funds tracked by Wall St. Rank hold SUPN as of Q3 2026.
- Freestone Grove Partners reported no remaining Supernus Pharmaceuticals position as of Q3 2026 after selling out during the quarter.
- Freestone Grove Partners sold 316,398 Supernus Pharmaceuticals shares in Q3 2026, an estimated $14.7M.
- Freestone Grove Partners first reported a position in Supernus Pharmaceuticals in Q4 2025 and held it in 3 quarters.
- Freestone Grove Partners's Supernus Pharmaceuticals position peaked at $33.1M in Q1 2026.
- 294 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q3 2026.
Based on Freestone Grove Partners's 13F filing for Q3 2026, filed 16 Nov 2026.